Evidence map›Paper›PMID 39174877›Full record

ArticleCancer biology & therapy2024

The anticancer mechanisms of

Guangqi Li, Qinhui Li, Yongqing Tong, Jin Zeng, Tiantian Dang, Ningai Yang, Yuning Zhou, Lei Ma, Qirui Ge, Zhijun Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pathogens (Basel, Switzerland) · 2026
    Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Guangqi LiMedical Laboratory Center, General Hospital of Ningxia Medical University, Yinchuan, China.
Qinhui LiCollege of Life Sciences, Ningxia University, Yinchuan, China.
Yongqing TongDepartment of Clinical laboratory, Renmin Hospital of Wuhan University, Wuhan, China.
Jin ZengCollege of Life Sciences, Ningxia University, Yinchuan, China.
Tiantian DangMedical Laboratory Center, General Hospital of Ningxia Medical University, Yinchuan, China.
Ningai YangInstitute of Medical Sciences, General Hospital of Ningxia Medical University, Yinchuan, China.
Yuning ZhouThe First Clinical Medical College, Ningxia Medical University, Yinchuan, China.
Lei MaCollege of Life Sciences, Ningxia University, Yinchuan, China.
Qirui GeThe First Clinical Medical College, Ningxia Medical University, Yinchuan, China.
Zhijun ZhaoMedical Laboratory Center, General Hospital of Ningxia Medical University, Yinchuan, China.ORCID 0000-0001-7645-9967

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung adenocarcinoma is the most prevalent subtype of lung cancer, which is the leading cause of cancer-related mortality worldwide.

Indexed as

Adenocarcinoma of LungApoptosisCell ProliferationLung NeoplasmsProtozoan ProteinsToxoplasmaA549 CellsCell MovementHumansProtein-Tyrosine KinasesSTAT3 Transcription FactorProtein-Tyrosine KinasesProtozoan ProteinsRop16 protein, Toxoplasma gondiiSTAT3 Transcription FactorA549cell phenotypelung cancerROP16STAT3Toxoplasma gondii

Identifiers

PMID39174877
PMCPMC11346528

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.